THE ROLE OF RIOCIGUAT IN THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH CONNECTIVE TISSUE DISEASE

Soluble guanylate cyclase (sGC) is a key signal-transduction enzyme activated by nitric oxide (NO). Binding NO with sGC - enzyme catalyzes the synthesis of a signal molecule of cyclic guanosine monophosphate (cGMP), which plays an important role in the regulation of processes that affect vascular tone, proliferation, fibrosis and inflammation. Impaired bioavailability and/or responsiveness to endogenous NO has been implicated in the pathogenesis of cardiovascular and other diseases. Pulmonary arterial hypertension (PAH) is a well-known complication of systemic connective tissue diseases (CTD) and ranks second among the most common types of PAH after idiopathic PAH (IPAH). The usage of organic nitrates and other NO donors has limitations, including non-specific interactions of NO with various biomolecules, lack of response and the development of tolerance following prolonged administration. Compounds that activate sGC in NO-independent manner might therefore provide considerable therapeutic advantages. The purpose of this article is to provide contemporary data on the management and treatment of patients, as well as the role of specific therapy and the place of riociguat in the treatment of patients with CTD associated PAH

pulmonary hypertension (PH), pulmonary arterial hypertension (PAH), pulmonary arterial hypertension associated with systemic connective tissue diseases (PAH CTD), PAH-specific therapy, riociguat

1. Evgenov O. et al. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov. 2006 September ; 5(9): 755–768.

2. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Respir J. 2015; 46(4): 903-75.

3. И. Е. Чазова, Т. В. Мартынюк. Монография «Легочная гипертензия». Практика. Москва, 2015; 17-108, 121-148, 189-227, 563-606.

4. Fayed H., Coghlan J.G. et al. Pulmonary Hypertension Associated with Connective Tissue Disease. Semin Respir Crit Care Med 2019;40:173–183. DOI https://doi.org/10.1055/s-0039-1685214

5. Zanatta1 E. et al. Pulmonary arterial hypertension in connective tissue disorders: Pathophysiology and treatment. Experimental Biology and Medicine 2019; 244: 120–131. DOI: 10.1177/1535370218824101

6. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336:111-117.

7. Мартынюк Т.В. Легочная гипертензия: диагностика и лечение, Москва, 2018, с. 148. / T.V. Martynyuk. Pulmonary hypertension: diagnostics and treatment, Moscow, 2018, p. 148. [in Russian].

8. С.Н. Авдеев и соавт. Легочная гипертензия: руководство для врачей. Москва, ГЭОТАР-Медиа, 2019; 386-406.

9. Беленков Ю.Н., Чазова И.Е. Первичная легочная гипертензия, Москва, Нолидж, 1999, с. 141. / Belenkov Yu.N., Chazova I.Ye. Primary pulmonary hypertension. Moscow: Nolidge, 1999. p. 141. [in Russian].

10. Nunes J.P. et al. Prevalence of auto-antibodies associated to pulmonary arterial hypertension in scleroderma – A review. Autoimmunity Reviews, Volume 17, Issue 12, December 2018, Pages 1186-1201. https://doi.org/10.1016/j.autrev.2018.06.009

11. Pan J., Lei L. et al. Comparison between the efficacy of combination therapy and monotherapy in connective tissue disease associated pulmonary arterial hypertension: a systematic review and meta-analysis. Clin Exp Rheumatol. 2018 Nov-Dec;36(6):1095-1102. Epub 2018 Jun 14.

12. Kuzuya K, Tsuji S, Matsushita M, et al. (March 26, 2019) Systemic Sclerosis and Systemic Lupus Erythematosus Overlap Syndrome with Pulmonary Arterial Hypertension Successfully Treated with Immunosuppressive Therapy and Riociguat. Cureus 11(3): e4327. doi: 10.7759/cureus.4327

13. Raina A. et al. Replacing a phosphodiesterase-5 inhibitor with riociguat in patients with connective tissue disease-associated pulmonary arterial hypertension: a case series. Pulm Circ. 2017 Sep; 7(3): 741–746. DOI: 10.1177/2045893217721694

14. Российское медицинское общество по артериальной гипертонии, РМОАГ. Клинические рекомендации «Легочная гипертензия», 2016 г. КР158 (доступно по ссылке: http://cr.rosminzdrav.ru/#!/recomend/136) (доступ по состоянию на 18.02.2019 г.).

15. А.А. Шмальц, С.В. Горбачевский. Риоцигуат и силденафил в лечении легочной гипертензии: сходства и различия. Пульмонология. 2016; 26 (1): 85–91.

16. Инструкция по медицинскому применению лекарственного препарата Адемпас. ЛП-002639 от 25.09.2019 г. (доступно по ссылке: https://grls.rosminzdrav.ru/GRLS.aspx?RegNumber=&MnnR=%d0%a0%d0%b8%d0%be%d1%86%d0%b8%d0%b3%d1%83%d0%b0%d1%82&lf=&TradeNmR=&OwnerName=&MnfOrg=&MnfOrgCountry=&isfs=0&isND=-1&regtype=1%2c&pageSize=10&order=RegDate&orderType=desc&pageNum=1(доступ по состоянию на 20.06.2019 г.).

17. A. Kambakamba et al. Acute hemodynamic effects of riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. European Respiratory Journal Sep 2018, 52 (suppl 62) PA3049; DOI: 10.1183/13993003.congress-2018.PA3049

18. Мершин К.В., Мартынюк Т.В. Место медикаментозной терапии в лечении хронической тромбоэмболической легочной гипертензии. Евразийский кардиологический журнал. 2014; 1: 113-118.

19. Ghofrani H-A et al. Riociguat for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med 2013; 369: 330–340.

20. Rubin LJ et al. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). Eur Respir 2015; 45: 1211–3.

21. Ghofrani H-A et al. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial. Lancet Respir Med 2016; 4: 361–71 (http://dx.doi.org/10.1016/S2213-2600(16)30019-4).

22. M.M. Hoeper, et al. Targeted therapy of pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018, Int J Cardiol (2018), https://doi.org/10.1016/j.ijcard.2018.08.082

23. Humbert M., Coghlan J.G., Ghofrani H.A. et al. Riociguat for the treatment of pulmonary arterial hypertension associated with

24. connective tissue disease: results from PATENT-1 and PATENT-2. Ann Rheum Dis 2016;0:1–5. doi:10.1136/annrheumdis-2015-209087 (available on: http://ard.bmj.com/content/early/2016/07/25/

25. annrheumdis-2015-209087.long) + supplementary appendix

26. Шмальц А.А., Горбачевский С.В. Биохимический путь оксида азота в терапии легочной артериальной гипертензии и результаты исследования RESPITE. Системные гипертензии. 2018; 15 (2). DOI: 10.26442/2075-082X_15.2

27. Taran I, Martynyuk T, Chazova I et al. Initial Riociguat Monotherapy and Transition from Sildenafil to Riociguat in Patients with Idiopathic Pulmonary Arterial Hypertension: Influence on Right Heart Remodeling and Right Ventricular–Pulmonary Arterial Coupling. Lung (2018) 196:745–753. https://doi.org/10.1007/ s00408-018-0160-4.

28. Guha M. First-in-class guanylate cyclase stimulator approved for PAH. Nat Biotechnol 2013; 31: 1064.

29. Платонов Д.Ю., Царева Н.А., Авдеев С.Н. Выживаемость пациентов с легочной артериальной гипертензией на фоне терапии таблетированными ЛАГ-специфическими препаратами. Системные гипертензии. 2017; 14 (3): 58–64.